Management of newborns exposed to maternal HIV infection

American Family Physician

Volumn 65, Issue 10, 2002, Pages

  Krist, Alex H ^a,b   Crawford Faucher, A M Y ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Fairfax Family Practice Residency   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; NEVIRAPINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; PROTOZOAL VACCINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; ANEMIA; CLINICAL PROTOCOL; EARLY DIAGNOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; LABOR; LABORATORY DIAGNOSIS; MATERNAL CARE; MATERNAL DISEASE; NEWBORN; NEWBORN CARE; NEWBORN SCREENING; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PREGNANCY; PSYCHOLOGICAL ASPECT; REVIEW; SOCIAL ASPECT; SOCIAL SUPPORT; VERTICAL TRANSMISSION; VIRUS DIAGNOSIS; VIRUS TRANSMISSION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HUMANS; INFANT CARE; INFANT, NEWBORN; PNEUMONIA, PNEUMOCYSTIS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TUBERCULOSIS, PULMONARY; ZIDOVUDINE;

EID: 0037093401     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Prevalence of HIV infection in the United States, 1984 to 1992
2. Prevalence and incidence of vertically acquired HIV infection in the United States
3. Incubation period of HIV-1 in perinatally infected children
4. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Centers for Disease Control and Prevention
5. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Centers for Disease Control and Prevention
6. Evaluation and medical treatment of the HIV-exposed infant
7. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model
8. Proposed definitions for in utero versus intrapartum transmission of HIV-1
9. Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease
10. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children
11. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment
12. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women
13. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
14. Report of the NIH panel to define principles of therapy of HIV infection
15. A meta-analytic evaluation of the polymerase chain reaction for the diagnosis of HIV infection in infants
16. Blood culture in the first 6 months of life for the diagnosis of vertically transmitted human immunodeficiency virus infection
17. Diagnosis of perinatal human immunodeficiency virus infection by polymerase chain reaction and p24 antigen detection after immune complex dissociation in an urban community hospital
18. The use of viral culture and p24 antigen testing to diagnose human immunodeficiency virus infection in neonates
19. Early diagnosis of human immunodeficiency virus infection in children less than 6 months of age: Comparison of polymerase chain reaction, culture, and plasma antigen capture techniques
20. Early detection of perinatal human immunodeficiency virus (HIV) type 1 infection using HIV RNA amplification and detection. New York City Perinatal HIV Transmission Collaborative Study
21. Immunization in special circumstances
22. Pneumocystis carinii pneumonia among US children with perinatally acquired HIV infection
23. 1995 Revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus
24. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. New York City Perinatal HIV Transmission Collaborative Study
25. Co-incidence of HIV/AIDS and tuberculosis-Chicago, 1982-1993
26. Tuberculosis
27. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins for persons with altered immunocompetence
28. Policy statement: Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis